|Articles|November 1, 2006

IMS Dec 06

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Amazon Pharmacy Launches GLP-1 Delivery Service

ByNicholas Jacobus

August 7th 2026

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million

ByNicholas Jacobus

August 7th 2026

FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma

ByNicholas Jacobus

August 7th 2026

The Structural Problems Causing the Pharma and Biotech Industries’ Compliance Failures

ByMike Hollan,Joseph Morwald

August 7th 2026

The challenge for pharmaceutical leaders is not just to become larger but to become more capable—the achievement of which may ultimately define the next era of pharmaceutical competition. Credit: Stock.Adobe.com/wladimir1804

The Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail

ByThani Jambulingam, PhD

August 7th 2026

IMS Dec 06

Related Content

Amazon Pharmacy Launches GLP-1 Delivery Service

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million

FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma

The Structural Problems Causing the Pharma and Biotech Industries’ Compliance Failures

The Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail

Trending on PharmExec

FDA Approves Moderna's mRNA-Based Flu Vaccine

Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton

Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs

FDA Approves Orezeyful for Narcolepsy Type 1 in Adults

Pharmaceutical Executive Daily: FDA Approves Orezeyful